Cinven’s indicative EUR 10 per share Synlab bid seen as below fair value
Cinven’s non-binding expression of interest for German laboratory diagnostic services provider Synlab at EUR 10 per share, announced on 13 March, is considered below fair value, two minority shareholders told Unquote sister publication Mergermarket.
More on Buyouts
Permira to acquire majority stake in Gruppo Florence
Existing shareholders including VAM Investments and management of the Italian fashion group will reinvest, while Italmobiliare will exit
Gyrus Capital acquires LRE Medical from KPS-backed AIS Global
Carve-out of German diagnostic equipment manufacturer comes over two years after first sale attempt
ESI Group draws EQT, Hg, Thoma Bravo interest
Listed French industrial software maker has drawn wide interest from sponsors and strategic players
Ambienta finalises third fund deployment with Gruppo Spaggiari Parma acquisition
Italian GP is investing in the educational software group in a primary deal from its EUR 635m, 2018-vintage fund
Latest News
Golding aims to raise EUR 350m for next buyout co-investment fund amid ‘unprecedented’ dealflow
Vehicle expects to make its first deals this year, providing additional equity for deals against a tough fundraising backdrop
Permira to acquire majority stake in Gruppo Florence
Existing shareholders including VAM Investments and management of the Italian fashion group will reinvest, while Italmobiliare will exit
Mimir Group ramps up global origination effort with London office and focus on life science carve-outs
Stockholm-based investor is considering divestments, although challenging market remains a barrier
Gyrus Capital acquires LRE Medical from KPS-backed AIS Global
Carve-out of German diagnostic equipment manufacturer comes over two years after first sale attempt